featured
6 Months vs 12 Months of Adjuvant Trastuzumab in Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
6 Months Versus 12 Months of Adjuvant Trastuzumab in Early Breast Cancer (PHARE): Final Analysis of a Multicentre, Open-Label, Phase 3 Randomised Trial
Lancet 2019 Jun 06;[EPub Ahead of Print], X Pivot, G Romieu, M Debled, JY Pierga, P Kerbrat, T Bachelot, A Lortholary, M Espié, P Fumoleau, D Serin, JP Jacquin, C Jouannaud, M Rios, S Abadie-Lacourtoisie, L Venat-Bouvet, L Cany, S Catala, D Khayat, L Gambotti, I Pauporté, C Faure-Mercier, S Paget-Bailly, J Henriques, JM GrouinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.